Industry / China
APP Pharma Finds Comfort In Heparin
March 2008 | Company News AlertBaxter's heparin production problems appear to have given a boost to APP Pharmaceuticals, which had been expecting a tough year after it parted company with its biotech interests Abraxis BioScience in November 2007. As part of the split, APP took on US$1bn debt, which was expected to weigh on the company while it brought its new Puerto Rican facility up to capacity. As it turns out, it has been a case of the right product at the right time for APP, as the new factory has given APP the slack to capitalise on Baxter's crisis and increase
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
